Evidence map›Paper›PMID 37236766›Full record

ArticleAdvances in pharmacology (San Diego, Calif.)2023

The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).

Kimberley Cousins, Chien-Chang Chen, Esha Sehanobish, Elina Jerschow

Open access · greenAbstract read
In one paragraph

Article in Advances in pharmacology (San Diego, Calif.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kimberley CousinsDivision of Rheumatology & Clinical Allergy and Immunology, Department of Medicine, University College of Medicine, University of Florida, Gainesville, FL, United States.
Chien-Chang ChenDivision of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
Esha SehanobishDivision of Allergy and Immunology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States.
Elina JerschowDivision of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, United States. Electronic address: jerschow.elina@mayo.edu.
Mayo Clinic · USAlbert Einstein College of Medicine · USUniversity of Florida · US

Funding

Th2A cells mediate outcomes of aspirin-exacerbated respiratory diseaseR21AI146804 · NIAID · MAYO CLINIC ROCHESTER · PI JERSCHOW, ELINA · 2020 to 2021
$456k
NIAID NIH HHS R21 AI146804
6 · The paper itself

Abstract

Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is characterized by nasal polyp formation, adult-onset asthma, and hypersensitivity to all cyclooxygenase-1 (COX-1) inhibitors. Oxygenated lipids are collectively known as oxylipins and are polyunsaturated fatty acids (PUFA) oxidation products. The most extensively researched oxylipins being the eicosanoids formed from arachidonic acid (AA). There are four major classes of eicosanoids including leukotrienes, prostaglandins, thromboxanes, and lipoxins. In N-ERD, the underlying inflammatory process of the upper and lower respiratory systems begins and occurs independently of NSAID consumption and is due to the overproduction of cysteinyl leukotrienes. Leukotriene mediators all induce edema, bronchoconstriction, and airway mucous secretion. Thromboxane A

Indexed as

Anti-Inflammatory Agents, Non-SteroidalRespiratory Tract DiseasesAdultAspirinEicosanoidsHumansLeukotrienesOxylipinsProstaglandinsAnti-Inflammatory Agents, Non-SteroidalAspirinEicosanoidsLeukotrienesOxylipinsProstaglandinsAspirin exacerbated respiratory disease (AERD)Cyclooxygenase-1 (COX-1)EicosanoidsNonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD)OxylipinsProstaglandin D2 (PGD2)

Identifiers

PMID37236766
PMCPMC10591515
OpenAlexW4315434098

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.